In this context, the phase-2 basket study, ROAR, evaluated the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK-inhibitor) in 33 patients with CCA. This evidence concerns the gene MAP2K7 and cholangiocarcinoma.